清除丙型肝炎病毒(HCV)可降低HIV/HCV合并感染者的免疫激活、微生物易位及HIV DNA水平
前瞻性研究连续纳入97例接受抗逆转录病毒治疗且经无干扰素方案获得持续病毒学应答的HIV/HCV合并感染者,在治疗前、治疗结束即刻及结束后1个月评估免疫激活标志物、HIV DNA载量及微生物易位标志物。治疗结束及结束后1个月,CD4+和CD8+ T细胞HLA-DR和CD38表达、proviral HIV DNA、sCD14、LPS、16S rDNA及D-二聚体均显著下降(P < .001),而PD-1、CD57、IL-6和hsCRP无变化。作者结论支持对所有HIV/HCV合并感染者进行HCV治疗,即使纤维化程度低。
要点
- HCV清除后CD4+和CD8+ T细胞HLA-DR和CD38表达显著下降(P < .001)。
- HCV清除后proviral HIV DNA、sCD14、LPS、16S rDNA及D-二聚体显著下降(P < .001)。
- PD-1、CD57、IL-6和hsCRP无变化,CD4+计数及CD4/CD8比值未增加。
核心结论
- HIV/HCV合并感染者清除HCV后,免疫激活标志物、proviral HIV DNA载量、微生物易位标志物及D-二聚体水平显著下降。
- 这些发现支持对所有HIV/HCV合并感染者进行HCV治疗,即使纤维化程度低。
研究设计与样本
- 前瞻性研究,连续纳入97例接受抗逆转录病毒治疗且经无干扰素方案获得持续病毒学应答的HIV/HCV合并感染者。
- 在治疗前、治疗结束即刻及治疗结束后1个月评估免疫激活标志物、HIV DNA载量及微生物易位标志物。
主要发现
- 治疗结束及结束后1个月,CD4+和CD8+ T细胞HLA-DR和CD38表达、proviral HIV DNA、sCD14、LPS、16S rDNA及D-二聚体均显著下降(P < .001)。
- CD4+和CD8+ T细胞PD-1和CD57表达及IL-6、hsCRP水平无变化。
- 免疫激活标志物、proviral HIV DNA及微生物易位标志物的改善未转化为CD4+ T细胞计数增加或CD4/CD8比值增加。
关键数值与推荐
- 治疗结束及结束后1个月,CD4+和CD8+ T细胞HLA-DR和CD38表达、proviral HIV DNA、sCD14、LPS、16S rDNA及D-二聚体较基线显著下降(P < .001)。
- CD4+和CD8+ T细胞PD-1和CD57表达及IL-6、hsCRP水平无显著变化。
- CD4+ T细胞计数及CD4/CD8比值无显著增加。
临床怎么用
- 作者结论支持对所有HIV/HCV合并感染者进行HCV治疗,即使纤维化程度低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are contradictory data about the influence that hepatitis C virus (HCV) has on immune activation and inflammation in patients coinfected with human immunodeficiency virus (HIV) and HCV. METHODS: HIV/HCV-coinfected patients receiving antiretroviral treatment who achieved a sustained virological response with interferon-free regimens were consecutively enrolled in a prospective study. The following factors were assessed before, immediately after the end of, and 1 month after the end of therapy: expression of HLA-DR/CD38, PD-1, and CD57 on CD4+ and CD8+ T-cells; measurement of the total HIV DNA load in peripheral blood mononuclear cells; and determination of plasma levels of soluble CD14 (sCD14), lipopolysaccharide (LPS), 16S ribosomal DNA (rDNA), interleukin 6 (IL-6), D-dimers, and high-sensitivity C-reactive protein (hsCRP). RESULTS: Ninety-seven patients were consecutively included. At the end of therapy and 1 month later, there were significant reductions in the expression of HLA-DR and CD38 in CD4+ and CD8+ T cells, as well as levels of proviral HIV DNA, sCD14, LPS, 16S rDNA, and D-dimer (P < .001). By contrast, the expression of PD-1 and CD57 in CD4+ and CD8+ T cells and levels of IL-6 and hsCRP did not change. The improvement in levels of immune activation markers, proviral HIV DNA, and microbial translocation markers did not translate into an increased CD4+ T-cell count or increased ratio of the CD4+ T-cell count to the CD8+ T-cell count. CONCLUSIONS: HCV eradication in HIV/HCV-coinfected patients results in significant decreases in levels of immune activation markers, proviral HIV DNA load, microbial translocation markers, and D-dimers. These findings support the use of HCV treatment for all HIV/HCV-coinfected patients, even those with low-grade fibrosis.
引用
- López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, et al. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018. PMID: 29986086. doi:10.1093/infdis/jiy136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。